Breast cancer screening in women at high risk using MRI

NMR in Biomedicine

Volumn 22, Issue 1, 2009, Pages 17-27

  Leach, Martin O ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

BRCA1; BRCA2; Breast cancer; Dynamic contrast enhanced (DCE); Genetic mutation; MRI; Screening

Indexed keywords

BRCA1; BRCA2; BREAST CANCER; DYNAMIC CONTRAST ENHANCED (DCE); GENETIC MUTATION; MRI;

DIAGNOSTIC RADIOGRAPHY; MAGNETIC RESONANCE IMAGING;

HEALTH RISKS;

BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN P53;

BREAST CANCER; CANCER DIAGNOSIS; CANCER MORPHOLOGY; CANCER RISK; CANCER SCREENING; CANCER STAGING; COST BENEFIT ANALYSIS; FEMALE; GENE MUTATION; HIGH RISK PATIENT; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; INTERMETHOD COMPARISON; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; X RAY;

BREAST NEOPLASMS; FEMALE; HEALTH PLAN IMPLEMENTATION; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MASS SCREENING; RISK FACTORS;

EID: 65349139634     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1326     Document Type: Review

References (56)

1. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996; 77: 2318-2324.
2. Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 1993; 52: 678-701.
3. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-792.
4. Robson M, Offit K. Clinical practice. Management of an inherited predisposition to breast cancer. N. Engl. J. Med. 2007; 357: 154-162.
5. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-1238.
6. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, Bowman R, Meyer KB, Haiman CA, Kolonel LK, Henderson BE, Le Marchand L, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Eccles D, Evans DG, Peto J, Fletcher O, Johnson N, Seal S, Stratton MR, Rahman N, ChenevixTrench G, Bojesen SE, Nordestgaard BG, Axelsson CK, Garcia-Closas M, Brinton L, Chanock S, Lissowska J, Peplonska B, Nevanlinna H, Fagerholm R, Eerola H, Kang D, Yoo KY, Noh DY, Ahn SH, Hunter DJ, Hankinson SE, Cox DG, Hall P, Wedren S, Liu J, Low YL, Bogdanova N, Schurmann P, Dork T, Tollenaar RA, Jacobi CE, Devilee P, Klijn JG, Sigurdson AJ, Doody MM, Alexander BH, Zhang J, Cox A, Brock IW, MacPherson G, Reed MW, Couch FJ, Goode EL, Olson JE, MeijersHeijboer H, van den OA, Uitterlinden A, Rivadeneira F, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Hopper JL, McCredie M, Southey M, Giles GG, Schroen C, Justenhoven C, Brauch H, Hamann U, Ko YD, Spurdle AB, Beesley J, Chen X, Mannermaa A, Kosma VM, Kataja V, Hartikainen J, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007; 447: 1087-1093.
7. Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA, Scollen S, Baynes C, Ponder BA, Chanock S, Lissowska J, Brinton L, Peplonska B, Southey MC, Hopper JL, McCredie MR, Giles GG, Fletcher O, Johnson N, Dos SS I, Gibson L, Bojesen SE, Nordestgaard BG, Axelsson CK, Torres D, Hamann U, Justenhoven C, Brauch H, Chang-Claude J, Kropp S, Risch A, Wang-Gohrke S, Schurmann P, Bogdanova N, Dork T, Fagerholm R, Aaltonen K, Blomqvist C, Nevanlinna H, Seal S, Renwick A, Stratton MR, Rahman N, Sangrajrang S, Hughes D, Odefrey F, Brennan P, Spurdle AB, Chenevix-Trench G, Beesley J, Mannermaa A, Hartikainen J, Kataja V, Kosma VM, Couch FJ, Olson JE, Goode EL, Broeks A, Schmidt MK, Hogervorst FB, Van't Veer LJ, Kang D, Yoo KY, Noh DY, Ahn SH, Wedren S, Hall P, Low YL, Liu J, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Sigurdson AJ, Stredrick DL, Alexander BH, Struewing JP, Pharoah PD, Easton DF. A common coding variant in CASP8 is associated with breast cancer risk. Nat. Genet. 2007; 39: 352-358.
8. Horwich A, Swerdlow AJ. Second primary breast cancer after Hodgkin's disease. Br. J. Cancer 2004; 90: 294-298.
9. Leach MO. MRI for breast cancer screening. Ann. Oncol. 2006; 17 Suppl 10: x325-x331.
10. Banks E, Reeves G, Beral V, Bull D, Crossley B, Simmonds M, Hilton E, Bailey S, Barrett N, Briers P, English R, Jackson A, Kutt E, Lavelle J, Rockall L, Wallis MG, Wilson M, Patnick J. Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the MillionWomen Study: cohort study. BMJ. 2004; 329: 477.
11. Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster V. Likelihood ratios for modern screening mammography. Risk of breast cancer based on age and mammographic interpretation. JAMA. 1996; 276: 39-43.
12. Mushlin AI, Kouides RW, Shapiro DE. Estimating the accuracy of screening mammography: a meta-analysis. Am. J. Prev. Med. 1998; 14: 143-153.
13. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Ford D, Peto J, Stoppa-Lyonnet D, Easton DF. and. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl. Cancer Inst. 1998; 90: 1138-1145.
14. Komenaka IK, Ditkoff BA, Joseph KA, Russo D, Gorroochurn P, Ward M, Horowitz E, El Tamer MB, Schnabel FR. The development of interval breast malignancies in patients with BRCA mutations. Cancer 2004; 100: 2079-2083.
15. Scheuer L, Kauff N, Robson M, Kelly B, Barakat R, Satagopan J, Ellis N, Hensley M, Boyd J, Borgen P, Norton L, Offit K. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J. Clin Oncol. 2002; 20: 1260-1268.
16. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF, Brekelmans CT, Klijn JG. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 2001; 345: 159-164.
17. Heywang-Kobrunner SH, Bick U, Bradley WG Jr, Bone B, Casselman J, Coulthard A, Fischer U, Muller-Schimpfle M, Oellinger H, Patt R, Teubner J, Friedrich M, Newstead G, Holland R, Schauer A, Sickles EA, Tabar L, Waisman J, Wernecke KD. International investigation of breast MRI: results of a multicentre study (11 sites) concerning diagnostic parameters for contrast-enhanced MRI based on 519 histopathologically correlated lesions. Eur. Radiol. 2001; 11: 531-546.
18. Harms SE, Flamig DP, Hesley KL, Meiches MD, Jensen RA, Evans WP, Savino DA, Wells RA. MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation. Radiology 1993; 187: 493-501.
19. Boetes C, Barentsz JO, Mus RD, van der Sluis RF, van Erning LJ, Hendriks JH, Holland R, Ruys SH. MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique. Radiology 1994; 193: 777-781.
20. Baum F, Fischer U, Vosshenrich R, Grabbe E. Classification of hypervascularized lesions in CE MR imaging of the breast. Eur. Radiol. 2002; 12: 1087-1092.
21. Gilles R, Guinebretiere JM, Toussaint C, Spielman M, Rietjens M, Petit JY, Contesso G, Masselot J, Vanel D. Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology 1994; 191: 633-638.
22. Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, Meschino WS, Piron CA, Narod SA. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004; 292: 1317-1325.
23. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, Muller SH, Meijer S, Oosterwijk JC, Beex LV, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG. Efficacy of MRI and mammography for breastcancer screening in women with a familial or genetic predisposition. N. Engl. J. Med. 2004; 351: 427-437.
24. Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, Gilbert FJ, Griebsch I, Hoff RJ, Kessar P, Lakhani SR, Moss SM, Nerurkar A, Padhani AR, Pointon LJ, Thompson D, Warren RM. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005; 365: 1769-1778.
25. Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, Kuhn W, Schild HH. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J. Clin. Oncol. 2005; 23: 8469-8476.
26. Lehman CD, Blume JD, Weatherall P, Thickman D, Hylton N, Warner E, Pisano E, Schnitt SJ, Gatsonis C, Schnall M, DeAngelis GA, Stomper P, Rosen EL, O'loughlin M, Harms S, Bluemke DA. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 2005; 103: 1898-1905.
27. Sardanelli F, Podo F, D'Agnolo G, Verdecchia A, Santaquilani M, Musumeci R, Trecate G, Manoukian S, Morassut S, De Giacomi C, Federico M, Cortesi L, Corcione S, Cirillo S, Marra V, Cilotti A, Di Maggio C, Fausto A, Preda L, Zuiani C, Contegiacomo A, Orlacchio A, Calabrese M, Bonomo L, Di Cesare E, Tonutti M, Panizza P, Del Maschio A. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. Radiology. 2007; 242: 698-715.
28. Hagen AI, Kvistad KA, Maehle L, Holmen MM, Aase H, Styr B, Vabo A, Apold J, Skaane P, Moller P. Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast. 2007; 16: 367-374.
29. Riedl CC, Ponhold L, Flory D, Weber M, Kroiss R, Wagner T, Fuchsjager M, Helbich TH. Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer, and premalignant lesions during surveillance of women at high risk for breast cancer. Clin Cancer Res. 2007; 13: 6144-6152.
30. Leach MO. Protocol 97PRT/4: National study of magnetic resonance imaging to screen women at genetic risk of breast cancer. Lancet 1997. http://www.thelancet.com/journals/lancet/misc/protocol/97PRT-4 (accessed 1 Oct 2008).
31. Brown J, Coulthard A, Dixon AK, Dixon JM, Easton DF, Eeles RA, Evans DGR, Gilbert FG, Hayes C, Jenkins JPR, Leach MO, Moss SM, Padhani AP, Pointon LJ, Ponder BAJ, Sloane JP, Turnbull LW, Walker LG, Warren RML, Watson W. Rationale for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer. Breast 2000; 9: 72-77.
32. Brown J, Coulthard A, Dixon AK, Dixon JM, Easton DF, Eeles RA, Evans DGR, Gilbert FG, Hayes C, Jenkins JPR, Leach MO, Moss SM, Padhani AP, Pointon LJ, Ponder BAJ, Sloane JP, Turnbull LW, Walker LG, Warren RML, Watson W. Protocol for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer. Breast 2000; 9: 78-82.
33. Brown J, Buckley D, Coulthard A, Dixon AK, Dixon JM, Easton DF, Eeles RA, Evans DG, Gilbert FG, Graves M, Hayes C, Jenkins JP, Jones AP, Keevil SF, Leach MO, Liney GP, Moss SM, Padhani AR, Parker GJ, Pointon LJ, Ponder BA, Redpath TW, Sloane JP, Turnbull LW, Walker LG, Warren RM. Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. Magn Reson Imaging 2000; 18: 765-776.
34. Leach MO, The MARIBS Study Group. Screening women at genetic risk of breast cancer using DCE-MRI: the effect of gene mutation status on detection sensitivity, specificity and cancer characteristics. Proceedings of the International Society of Magnetic Resonance in Medicine. 2006; 14: 297.
35. NHSBSP. Cancer Screening Programmes. National Breast Screening Programme 2004 review. 2005. http://cancerscreening.org.uk/ breastscreen/publications/2004review.html (accessed 1 Oct 2008).
36. Warren RM, Pointon L, Thompson D, Hoff R, Gilbert FJ, Padhani A, Easton D, Lakhani SR, Leach MO. Reading protocol for dynamic contrast-enhanced MR images of the breast: sensitivity and specificity analysis. Radiology 2005; 236: 779-788.
37. Warren RM, Thompson D, Pointon LJ, Hoff R, Gilbert FJ, Padhani AR, Easton DF, Lakhani SR, Leach MO. Evaluation of a prospective scoring system designed for a multicenter breast MR imaging screening study. Radiology 2006; 239: 677-685.
38. Sardanelli F, Podo F. Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection? Eur. Radiol. 2007; 17: 873-887.
39. Lord SJ, Lei W, Craft P, Cawson JN, Morris I, Walleser S, Griffiths A, Parker S, Houssami N. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur. J. Cancer. 2007; 43: 1905-1917.
40. Bermejo-Perez MJ, Marquez-Calderon S, Llanos-Mendez A. Cancer surveillance based on imaging techniques in carriers of BRCA1/2 gene mutations: a systematic review. Br. J. Radiol. 2008; 81: 172-179.
41. Veltman J, Mann R, Kok T, Obdeijn IM, Hoogerbrugge N, Blickman JG, Boetes C. Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI. Eur. Radiol. 2008; 18: 931-938.
42. Schrading S, Kuhl CK. Mammographic, US, and MR imaging phenotypes of familial breast cancer. Radiology. 2008; 246: 58-70.
43. Kuhl CK, Schrading S, Bieling HB,Wardelmann E, Leutner CC, Koenig R, Kuhn W, Schild HH. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet. 2007; 370: 485-492.
44. Lakhani SR. The pathology of familial breast cancer: Morphological aspects. Breast Cancer Res. 1999; 1: 31-35.
45. Tilanus-Linthorst M, Verhoog L, Obdeijn IM, Bartels K, Menke-Pluymers M, Eggermont A, Klijn J, Meijers-Heijboer H, van der KT, Brekelmans C. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent falsenegative mammography. Int. J. Cancer 2002; 102: 91-95.
46. Anderson J, Walker LG, Leach MO. Magnetic resonance imaging: an acceptable way of screening women with a family history of breast cancer. Breast Cancer Res Treat 2004; 88: S188. 27th Annual Charles A Colman San Antonio Breast Cancer Symposium.
47. Griebsch I, Brown J, Boggis C, Dixon A, Dixon M, Easton D, Eeles R, Evans DG, Gilbert FJ, Hawnaur J, Kessar P, Lakhani SR, Moss SM, Nerurkar A, Padhani AR, Pointon LJ, Potterton J, Thompson D, Turnbull LW, Walker LG, Warren R, Leach MO. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer. Br. J. Cancer 2006; 95: 801-810.
48. Norman RP, Evans DG, Easton DF, Young KC. The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30-49. Eur. J. Health Econ. 2007; 8: 137-144.
49. NICE. Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care - update. 2006; 1-75. National Institute for Health and Clinica Excellence, London. http://www.nice.org.uk/guidance/cg41 (accessed 1 Oct 2008).
50. Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, Garber AM. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 2006; 295: 2374-2384.
51. Lee JM, Kopans DB, McMahon PM, Halpern EF, Ryan PD,Weinstein MC, Gazelle GS. Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging: Markov Monte Carlo decision analysis. Radiology. 2008; 246: 763-771.
52. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007; 57: 75-89.
53. Parmigiani G, Berry DA, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998; 62: 145-58.
54. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat. Med. 2004; 23: 1111-1130.
55. Antoniou AC, Pharoah PP, Smith P, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br. J. Cancer 2004; 91: 1580-1590.
56. Tilanus-Linthorst MM, Obdeijn IM, Hop WC, Causer PA, Leach MO, Warner E, Pointon L, Hill K, Klijn JG, Warren RM, Gilbert FJ. BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Cancer Res. 2007; 13: 7357-7362.